Pharmacological activation of PPARγ improves insulin resistance in diabetes and has been reported to decrease liver damage in NAFLD by restoring adipose tissue insulin sensitivity, decreasing FFA flux to the liver [84, 85]. This evidence concerns the gene PPARG and diabetes mellitus.